# Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone

> **NCT00600756** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 798 (actual)

## Conditions studied

- Schizophrenic Disorders

## Interventions

- **DRUG:** Quetiapine XR
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00600756
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 798 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600756, "Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00600756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*